Current Opinion in Structural Biology, volume 72, pages 135-144
Deep learning approaches for de novo drug design: An overview
Mingyang Wang
1
,
Zhe Wang
1
,
Huiyong Sun
2
,
Jingjing Wang
1
,
Chao Shen
1
,
Gaoqi Weng
1
,
Xin Chai
1
,
Honglin Li
3, 4
,
Dongsheng Cao
5
,
Publication type: Journal Article
Publication date: 2022-02-01
scimago Q1
wos Q1
SJR: 2.824
CiteScore: 12.2
Impact factor: 6.1
ISSN: 0959440X, 1879033X
Molecular Biology
Structural Biology
Abstract
De novo drug design is the process of generating novel lead compounds with desirable pharmacological and physiochemical properties. The application of deep learning (DL) in de novo drug design has become a hot topic, and many DL-based approaches have been developed for molecular generation tasks. Generally, these approaches were developed as per four frameworks: recurrent neural networks; encoder-decoder; reinforcement learning; and generative adversarial networks. In this review, we first introduced the molecular representation and assessment metrics used in DL-based de novo drug design. Then, we summarized the features of each architecture. Finally, the potential challenges and future directions of DL-based molecular generation were prospected.
Found
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Profiles